Author Archives: Catarina Silva, MSc

EMA Reviewing Belantamab Mafodotin for Heavily Pretreated Multiple Myeloma

The European Medicines Agency has agreed to review the application of  GlaxoSmithKline‘s belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. Specifically, the marketing authorization application is for people with relapsed or refractory disease who received prior treatment with an …